TELOTRISTAT ETIPRATE (LX1606) VS PLACEBO IN PATIENTS WITH CARCINOID SYNDROME REFRACTORY TO SOMATOSTATIN ANALOG THERAPY
Type d'étude :
Phase III
Promoteur :
Lexicon
Etat actuel de l'étude :
Terminée aux inclusions
Première présentation au congrès :
ESMO 2015
Principale publication :
Kulke, JCO 2017
A Phase 3, Randomized, Placebo-controlled, Parallel Group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome Refractory to Somatostatin Analog (SSA) Therapy
